PF 06667272
Alternative Names: PF06667272Latest Information Update: 08 Mar 2018
Price :
$50 *
At a glance
- Originator Pfizer
- Class Hepatoprotectants
- Mechanism of Action Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 30 Jan 2018 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Belgium (PO) (Pfizer pipeline, March 2018)
- 28 Apr 2017 Pfizer plans to initiate a phase I trial for an undefined indication (In volunteers) in Belgium
- 19 Apr 2017 Preclinical trials in Undefined indication in Belgium (unspecified route)